Primary Bronchial/Tracheal Epithelial Cells; Normal, Human (ATCC^® PCS-300-010^™)

1. Obtain one Bronchial/Tracheal Epithelial Cell Growth Kit from the freezer; make sure that the caps of all components are tight.
2. Thaw the components of the growth kit just prior to adding them to the basal medium. Warm the L-glutamine component in a 37°C water bath and shake to dissolve any precipitates prior to adding to the basal medium.
3. Obtain one bottle of Airway Epithelial Cell Basal Medium (485 mL) from cold storage.
4. Decontaminate the external surfaces of all growth kit component vials and the basal medium bottle by spraying them with 70% ethanol.
5. Using aseptic technique and working in a laminar flow hood or biosafety cabinet, transfer the indicated volume of each growth kit component, as indicated in Table 1, to the bottle of basal medium using a separate sterile pipette for each transfer.

Table 1. Brochial/Tracheal Epithelial Cell Growth Kit Components 

Component	Volume	Final Concentration
HLL Supplement	1.25 mL	HSA 500 mg/mL Linoleic Acid 0.6 mM Lecithin 0.6 mg/mL
L-Glutamine	15 mL	6 mM
Extract P	2.0 mL	0.4%
Airway Epithelial Cell Supplement	5.0 mL	Epinephrine 1.0 mM Transferrin 5 mg/mL T3 10 nM Hydrocortisone 5 mg/mL rh EGF 5 ng/mL rh Insulin 5 mg/mL

 

Antimicrobials and phenol red are not required for proliferation but may be added if desired. The recommended volume of either of the optional components to be added to the complete growth media is summarized in Table 2.

Table 2. Addition of Antimicrobials/Antimycotics and Phenol Red (Optional)

Component	Volume	Final Concentration
Penicillin-Streptomycin-Amphotericin B Solution	0.5 mL	Penicillin: 10 Units/mL Streptomycin: 10 µg/mL Amphotericin B: 25 µg/mL
Phenol Red	0.5 mL	33 µM



6. Tightly cap the bottle of complete growth medium and swirl the contents gently to assure a homogeneous solution. Do not shake forcefully to avoid foaming. Label and date the bottle.
7. Complete growth media should be stored in the dark at 2°C to 8°C (do not freeze). When stored under these conditions, complete growth media is stable for 30 days.

1. Passage normal bronchial/tracheal cells when the culture has reached approximately 70% to 80% confluence.
2. Warm both the Trypsin-EDTA for Primary Cells (ATCC PCS-999-003) and the Trypsin Neutralizing Solution (ATCC PCS-999-004) to room temperature prior to dissociation. Warm the complete growth medium to 37°C prior to use with the cells.
3. For each flask, carefully aspirate the spent media without disturbing the monolayer.
4. Rinse the cell layer one time with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual medium.
5. Add pre-warmed trypsin-EDTA solution (1 to 2 mL for every 25 cm²) to each flask.
6. Gently rock each flask to ensure complete coverage of the trypsin-EDTA solution over the cells, and then aspirate the excess fluid off of the monolayer.
7. Observe the cells under the microscope. When the cells pull away from each other and round up (typically within 1 to 3 minutes), remove the flask from the microscope and gently tap it from several sides to promote detachment of the cells from the flask surface.
8. When the majority of cells appear to have detached, quickly add an equal volume of the Trypsin Neutralizing Solution (ATCC PCS-999-004) to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.
9. Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the culture flask.
10. Add 3 to 5 mL D-PBS (ATCC 30-2200) to the tissue culture flask to collect any additional cells that might have been left behind.
11. Transfer the cell/D-PBS suspension to the centrifuge tube containing the trypsin-EDTA-dissociated cells.
12. Repeat steps 10 and 11 as needed until all cells have been collected from the flask.
13. Centrifuge the cells at 150 x g for 3 to 5 minutes.
14. Aspirate neutralized dissociation solution from the cell pellet and resuspend the cells in 2 to 8 mL fresh, pre-warmed, complete growth medium.
15. Count the cells and seed new culture flasks at a density of 5,000 viable cells per cm². 
16. 16. Place newly seeded flasks in a 37°C, 5% CO₂ incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding.

Cipollina C, Di Vincenzo S, Gerbino S, et al. Dual anti-oxidant and anti-inflammatory actions of the electrophilic cyclooxygenase-2-derived 17-oxo-DHA in lipopolysaccharide-and cigarette smoke-induced inflammation. Biochim Biophys Acta 1840(7):2299-309, 2014. PubMed: 24594225

Pace E, Di Sano C, Sciarrino S, et al. Cigarette smoke alters IL-33 expression and release in airway epithelial cells. Biochim Biophys Acta 1842(9):1630-7, 2014. PubMed: 24931101

Halim NHA, et al. Isolation and Characterization of Cancer Stem Cells of the Non-Small-Cell Lung Cancer (A549) Cell Line. Methods Mol Biol 1516:371-388, 2016. PubMed: 27032945

Mantalbano AM, et al. Autocrine Acetylcholine, Induced by IL-17A via NFkB and ERK1/2 Pathway Activation, Promotes MUC5AC and IL-8 Synthesis in Bronchial Epithelial Cells. Mediators Inflamm 2016:9063842, 2016. PubMed: 27298519

Pace E, et al. Effects of ceftaroline on the innate immune and on the inflammatory responses of bronchial epithelial cells exposed to cigarette smoke. Toxicol Lett 258:216-226, 2016. PubMed: 27397760

Paplinska-Goryca M, et al. The expression of the eotaxins IL-6 and CXCL8 in human epithelial cells from various levels of the respiratory tract. Cell Mil Biol Lett 18(4):612-30, 2013. PubMed: 24297684

Walimbe T, el al. An in vitro scaffold-free epithelial-fibroblast coculture model for the larynx. Laryngoscope 127(6):E185-E192, 2017. PubMed: 27859361

Branscome H. Inflammatory Profiles of Asthma and COPD Primary Human Bronchial Epithelial Cells in Response to LPS and an Inflammatory Inhibitor. George Mason University, 2017. DOI: 10.13021/G8VM3Q

Ferraro M, et al. Formoterol and fluticasone propionate combination improves histone deacetylation and anti-inflammatory activities in bronchial epithelial cells exposed to cigarette smoke. Biochim Biophys Acta 1863(7):1718-1727, 2017. PubMed: 28483577

Huang X, et al. Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation. Am J Transl Res 9(3):999-1011, 2017. PubMed: 28386328